US Patent

US8536163 — Therapeutic compositions

Method of Use · Assigned to Leo Laboratories Ltd · Expires 2026-12-18 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of stabilizing the anticancer agent ingenol angelate by dissolving it in an aprotic solvent with an acidic buffer.

USPTO Abstract

Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Drugs covered by this patent

Picato (INGENOL MEBUTATE) · Leo Labs

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1440`	—	Picato
`U-1440`	—	Picato

Patent Metadata

Patent number: US8536163
Jurisdiction: US
Classification: Method of Use
Expires: 2026-12-18
Drug substance claim: No
Drug product claim: No
Assignee: Leo Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.